Abstract
CD1d-restricted invariant NKT (iNKT) cells are a group of innate-like regulatory T cells that recognize lipid antigens. Both mouse modeling experiments and human clinical studies have suggested a key role for iNKT cells in anti-HBV immunity and these potent T cells can be explored as a novel therapeutic target for anti-HBV treatment. We aim to humanize mice in the CD1d/iNKT cell lipid presentation system and provide new research tools for identifying novel anti-HBV agents.
Highlights
Hepatotropic viruses are known as “silent killers”, as they can manifest disease without visible symptoms
Chronic Hepatitis B virus (HBV) infection can lead to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC) [1], and kills approximately one million people each year [2]
While newer nucleoside analogues (NAs) are less vulnerable to the development of drug resistance compared to previous NA drugs, complete clearance of viral infection is not achieved under this regimen [6]
Summary
Hepatotropic viruses are known as “silent killers”, as they can manifest disease without visible symptoms. Chronic HBV carriers include those whose blood contains HBV viral particles six months after infection [4]. Therapy for chronic hepatitis B (CHB) includes the use of nucleotide/nucleoside analogues (NAs) and Type I interferons (IFN-α). These treatments are not always available, and are only effective in controlling the infection but not eliminating the virus. During chronic exposure to HBV, there is persistent inflammation accompanied by liver damage and cell death. These factors give rise to chronic liver disease [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
